EUVIMEDEUVIMED entdecken
Open Access

Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras

Jake Sheraj Jacob, Anjiya Shaikh, Karthik Goli, Nicole E Rich, Jihane N Benhammou, Aijaz Ahmed, Donghee Kim, Abbas Rana, John A Goss, Susanna Naggie, Tzu-Hao Lee, Fasiha Kanwal und 1 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac821 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Jake Sheraj Jacob und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Coinfection, Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with human immunodeficiency virus (HIV) with and without hepatitis C virus (HCV) coinfection had poor outcomes after liver transplant (LT). Integrase strand transfer inhibitors (INSTIs) and direct-acting antivirals (DAAs) have changed the treatment landscape for HIV and HCV, respectively, but their impact on LT outcomes remains unclear.

Methods

This retrospective analysis of adults with HIV monoinfection (n = 246) and HIV/HCV coinfection (n = 286) who received LT compared mortality in patients with HIV who received LT before versus after approval of INSTIs and in patients with HIV/HCV coinfection who received LT before versus after approval of DAAs. In secondary analysis, we compared the outcomes in the different eras with those of propensity score–matched control cohorts of LT recipients without HIV or HCV infection.

Results

LT recipients with HIV monoinfection did not experience a significant improvement in survival between the pre-INSTI and INSTI recipients with HIV (adjusted hazard ratio [aHR], 0.70 [95% confidence interval {CI}, .36–1.34]). However, recipients with HIV/HCV coinfection in the DAA era had a 47% reduction (aHR, 0.53 [95% CI, .31–9.2] in 1-year mortality compared with coinfected recipients in the pre-DAA era. Compared to recipients without HIV or HCV, HIV-monoinfected recipients had higher mortality during the pre-INSTI era, but survival was comparable between groups during the INSTI era. HIV/HCV-coinfected recipients also experienced comparable survival during the DAA era compared to recipients without HCV or HIV.

Conclusions

Post-LT survival for people with HIV monoinfection and HIV/HCV coinfection has improved with the introduction of INSTI and DAA therapy, suggesting that LT has become safer in these populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationCoinfectionHepatitis C, ChronicHepatitis CHIV InfectionsAdultHumansAntiviral AgentsHepacivirusHIVRetrospective StudiesIntegrases

Stichwörter der Autor:innen

DAAHCVHIVINSTItransplant

Substanzen

Antiviral AgentsIntegrases

Autor:innen und Institutionen

  • Department of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Internal Medicine, University of Connecticut, Mansfield, Connecticut, USA.
  • Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Gastroenterology and Hepatology, University of California, Los Angeles, California, USA.
  • Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
  • Hepatology Program, Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas, USA.

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Cancer Institute
  • NIH

Zitieren

APA

Jacob, J. S., Shaikh, A., Goli, K., Rich, N. E., Benhammou, J. N., Ahmed, A., Kim, D., Rana, A., Goss, J. A., Naggie, S., Lee, T. H., Kanwal, F., & Cholankeril, G. (2023). Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac821

Vancouver

Jacob JS, Shaikh A, Goli K, Rich NE, Benhammou JN, Ahmed A, et al. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac821

BibTeX
@article{Jacob2023,
  author = {Jacob, Jake Sheraj and Shaikh, Anjiya and Goli, Karthik and Rich, Nicole E and Benhammou, Jihane N and Ahmed, Aijaz and Kim, Donghee and Rana, Abbas and Goss, John A and Naggie, Susanna and Lee, Tzu-Hao and Kanwal, Fasiha and Cholankeril, George},
  title = {Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac821}
}
Kostenlos starten →